Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Puri Website

Anu Puri, Ph.D.

Portait Photo of Anu Puri
Basic Research Laboratory
Staff Scientist
Center for Cancer Research
National Cancer Institute
Building 469, Room 216A
Frederick, MD 21702-1201


Dr. Puri received her Ph.D. degree in chemistry from the Central Drug Research Institute, Lucknow, India studying the chemical synthesis of modified phospholipids and possible use of their liposomes in drug delivery. Currently she holds the Research Biologist position at the CCR Nanobiology Program, NCI-Frederick, NIH. Her research revolves around several themes including (a) Cell Biology of Viral Entry, (b) Development of Lipid-Based Nanoparticles for Targeted Delivery of Cancer Therapeutics (c) Development of nano-scale diagnostic tools for detection of pathogens and cancer biomarkers, and (d) Mechanisms of opportunistic infections in AIDS and related diseases.


My area of research focuses on the mechanisms of entry pathways of enveloped viruses. Using cell biological, biophysical, biochemical approaches, I have studied the assemblies of molecular scaffolds of viral proteins and their receptors. Enveloped animal viruses deliver their genetic material to the cell by fusion of their membranes with those of the target cell. I have examined fusion mechanisms of members of rhabdo, orthomyxo, paramyxo and retrovirus family. My interest lies in elucidating the regulation of membrane fusion by plasma membrane lipid counter parts. The knowledge gained from my research has implications in the design of inhibitors of viral entry and the development of vaccines that prevent viral infection.

Recently I have embarked upon the development of lipid-based nanoparticles for delivery of toxic drugs. I plan to develop liposomes bearing payload of drugs with imaging and targeting capabilities. My focus is to modify the building blocks of liposomes (phospholipids) to generate these particles, which will result in on-demand triggered release potential. My long-term goal is to develop these state-of the art liposomes compatible for delivery of anti-cancer agents to patients.

This page was last updated on 7/14/2014.